Gilead Sciences Presents Groundbreaking Data on Primary Biliary Cholangitis and Viral Hepatitis at EASL 2026

At the European Association for the Study of the Liver (EASL) Congress 2026, Gilead Sciences, Inc. (Nasdaq: GILD) unveiled new clinical insights aimed at advancing treatment options for primary biliary cholangitis (PBC) and viral hepatitis. The presentations, delivered during the May 27-30 event in Barcelona, highlight the company’s commitment to addressing critical gaps in liver disease management.

Advancing PBC Treatment with Livdelzi

Gilead’s focus on PBC centered around Livdelzi® (seladelpar), a first-in-class delpar (selective PPAR-delta agonist) approved for treating PBC in combination with ursodeoxycholic acid (UDCA) for patients with inadequate responses or as monotherapy for those unable to tolerate UDCA. The company presented findings from 29 abstracts, including late-breaking data from the Phase 3 RESPONSE trial (NCT04620733) and interim results from the ASSURE study (NCT03301506).

The RESPONSE trial data evaluated Livdelzi’s efficacy and safety in PBC patients with risk factors for disease progression, such as elevated liver stiffness and metabolic syndrome. Meanwhile, the ASSURE study explored the relationship between biochemical response and liver stiffness trends over 36 months, particularly in individuals with alkaline phosphatase (ALP) levels between 1 to 1.67x the upper limit of normal (ULN). These findings, according to Dr. Swati Tole, Senior Vice President of Clinical Development at Gilead, provide a “multidimensional view of Livdelzi’s potential” to address both disease activity and patient-reported symptoms like pruritus.

Expanding Viral Hepatitis Research

In addition to PBC, Gilead shared updates on its viral hepatitis initiatives, emphasizing the need for innovative therapies to combat persistent challenges in the field. While specific details about new compounds were not disclosed, the company reiterated its dedication to “advancing understanding and care” through ongoing research and collaboration with the global medical community.

Implications for Patient Care

The